A. M. Ginsberg and M. Spigelman, Challenges in tuberculosis drug research and development, Nat Med, vol.13, pp.290-294, 2007.

C. Lienhardt and P. Nahid, Advances in clinical trial design for development of new TB treatments: A call for innovation, PLoS Med, vol.16, issue.3, p.1002769, 2019.
URL : https://hal.archives-ouvertes.fr/inserm-02170758

P. Phillips, C. D. Mitnick, J. D. Neaton, P. Nahid, C. Lienhardt et al., Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape, PLoS Med, vol.16, issue.3, p.1002767, 2019.
URL : https://hal.archives-ouvertes.fr/inserm-02170885

G. Davies, M. Hoelscher, M. Boeree, and D. Hermann, Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs, PLoS Med, vol.16, issue.7, p.1002851, 2019.

C. Lienhardt, P. Nahid, M. L. Rich, C. Bansbach, E. A. Kendall et al., Target regimen profiles for treatment of tuberculosis: a WHO document, Eur Respir J, vol.49, pp.2352-2016, 2017.

S. Tiberi, N. Du-plessis, G. Walzl, M. J. Vjecha, M. Rao et al., Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies, Lancet Infect Dis, vol.18, pp.183-98, 2018.

, on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation (EC) No 726/2004 of the European Parliament and of the Council, European Commission. Commission Regulation, issue.507, 2006.

A. European-medicines, Report on ten years of experience at the European Medicines Agency, 2019.

, Guidance for Industry Expedited Programs for Serious Conditions-Drugs and Biologics, US Food and Drug Administration, 2014.

A. European-medicine, Note for guidance on the evaluation of medicinal products for treatment of bacterial infections to address the clinical development of new agents to treat disease due to Mycobacterium tuberculosis, 2017.

. Us-fda, Development of new tuberculosis drug regimens-scientific and clinical design considerations, 2017.

. Us-fda, Pre-IND consultative process, 2016.

, Geneva: World Health Organization, Compendium of WHO guidelines and associated standards, 2018.

, World Health Organization. WHO handbook for guideline development, 2014.

G. H. Guyatt, A. D. Oxman, R. Kunz, J. Woodcocke, J. Brozeka et al., Going from evidence to recommendations, BMJ, vol.336, pp.1049-51, 2008.

E. Cox and K. Laessig, FDA Approval of Bedaquiline-The benefit-risk balance for drug-resistant tuberculosis, N Engl J Med, vol.371, 2014.

, World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance (WHO/HTM/TB/2013.6). Geneva: World Health Organization, 2013.

, World Health Organization. Treatment guidelines for multidrug-and rifampicin-resistant tuberculosis, Geneva: World Health Organization, 2018.

, World Health Organization. Introduction and rational use of new drugs / regimens for the treatment of tuberculosis in countries, 2019.

, Report of the technical consultation on advances in clinical trial design for development of new TB treatments. Glion-sur-Montreux

P. Nahid, J. Saukkonen, M. Kenzie, W. R. Johnson, J. L. Phillips et al., Tuberculosis biomarker and surrogate endpoint research roadmap, Am J Respir Crit Care Med, vol.184, issue.8, pp.972-979, 2011.

N. Rockwood, E. Du-bruyn, T. Morris, and R. J. Wilkinson, Assessment of treatment response in tuberculosis, Expert Rev Respir Med, vol.10, issue.6, pp.643-654, 2016.

P. P. Phillips, G. R. Davies, and D. A. Mitchison, Biomarkers for tuberculosis disease activity, cure, and relapse, Lancet Infect. Dis, vol.10, issue.2, pp.70256-70263, 2010.

R. Colangeli, H. Jedrey, S. Kim, R. Connell, S. Ma et al., Bacterial Factors That Predict Relapse after Tuberculosis Therapy, N Engl J Med, vol.379, issue.9, pp.823-833, 2018.

E. M. Svensson, R. J. Svensson, T. Brake, L. Boeree, M. J. Heinrich et al., The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis, Clin Infect Dis, vol.67, issue.1, pp.34-41, 2018.

F. Us and A. Drug, Multiple Endpoints in Clinical Trials Guidance for Industry, 2017.

L. Mauri and D. Rb, Challenges in the design and interpretation of noninferiority trials, N Engl J Med, vol.377, pp.1357-67, 2017.

D. Food and . Administration, Non-Inferiority Clinical Trials to Establish Effectiveness; Guidance for Industry, 2016.

E. Cpmp, Points to consider on switching between superiority and non-inferiority, 2000.

. Ich and . Ich, Harmonised Tripartite Guideline: Statistical Principles for Clinical Trials E9 Current Step 4 version, 1998.

, Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project, N Engl J Med, vol.303, issue.18, pp.1038-1079, 1980.

D. Centers-for and . Control, Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations-United States, MMWR Morb Mortal Wkly, vol.50, pp.733-738, 2001.

, Evaluating Newly Approved Drugs for Multidrug-resistant TB (endTB clinical trial), 2019.

, World Health Organization. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update (WHO/HTM/TB/2011.6). Geneva: World Health Organization, 2011.

, Geneva: World Health Organization, WHO treatment guidelines for drug-resistant tuberculosis-2016 update (WHO/HTM/TB/2016.04), 2016.

, Geneva: World Health Organization, WHO consolidated guidelines on drug-resistant tuberculosis treatment (WHO/CDS/TB/2019.7), 2019.

P. P. Phillips, K. E. Dooley, S. H. Gillespie, N. Heinrich, J. E. Stout et al., A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment followup (STEP), BMC Med, vol.14, p.27004726, 2016.

, Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment-2017. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis, Lancet, vol.392, issue.18, pp.31644-31645, 2018.

G. R. Davies, P. P. Phillips, and T. Jaki, Adaptive clinical trials in tuberculosis: applications, challenges and solutions, Int J Tuberc Lung Dis, vol.19, issue.6, pp.626-660, 2015.